Xencor Inc (XNCR) Stock Price & Analysis

Xencor Inc (XNCR) fell 0.04% to USD 26.61 as of September 8, 2026 at 05:45 UTC, according to Nexqual real-time market data.

XNCR last closed at USD 26.61; the session ranged USD 25.4–26.76 on volume of 919,792 shares. Market capitalization is —, with a 52-week range of USD 8.25–30.61 (NGM). Source: Nexqual, September 8, 2026 at 05:45 UTC.

Key Statistics (as of September 8, 2026 at 05:45 UTC)

Technical Analysis (XNCR)

Nexqual's technical model rates XNCR "STRONG BUY" based on 5 bullish and 0 bearish signals across 128 daily candles, as of September 8, 2026 at 05:45 UTC.

From Xencor Inc's Latest SEC 10-K Filing (filed 2026-02-25)

Key Strengths & Strategy (as disclosed to the SEC)

• Drug Development Process In the United States, the FDA regulates drugs and biologic products under the Federal Food, Drug and Cosmetic Act (FDCA), its implementing regulations, and other laws including, in the case of biologics, the Public Health Service Act.
• Biologics require the submission of a Biologics License Application (BLA) to the FDA and approval of the BLA by the FDA before marketing in the United States.
• Protect and expand our intellectual property portfolio We seek to protect our proprietary XmAb technologies and XmAb drug candidates by filing and prosecuting patents in the United States and other jurisdictions.
• Where appropriate, we pursue the expansion and extension of patent coverage for our proprietary and partnered programs incorporating our XmAb technologies. 5 D.

Partnerships

• Master Services Agreement with Kapadi (formerly OncoBay Clinical, Inc.) In August 2023, we entered into a master services agreement with OncoBay Clinical, Inc., now known as Kapadi, for CROs services supporting clinical trial management and development (including site selection, study design, site monitoring, management and training, and patient selection).
• License Agreement with BIO-TECHNE In April 2021, we entered into a non-exclusive license agreement with BIO-TECHNE for a recombinant monoclonal antibody reactive with human CLDN6, which is used in our XmAb541 program.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 05:45 UTC. This page is informational and not investment advice.